XRN Stock Forecast & Price Target

Chiron Real Estate is benefiting from a deliberate pivot away from slower-growth medical office assets toward senior housing operating properties, a segment supported by powerful demographic demand, sharply constrained new supply, and persistent rent growth above inflation. Its early execution is encouraging: since June 2026 SHOP exposure has risen to about 25% of the portfolio, the company has closed $249mm of acquisitions, sold $217mm of IRF assets at a 7.3% cash cap rate, and reduced net debt to adjusted EBITDAre to 6.0x from 6.6x. With high-quality assets acquired at attractive yields, a strengthened management team, and a self-funded capital recycling plan that avoids heavy common equity dilution, the fundamentals point to improving NAV, better growth visibility, and eventual multiple expansion.

Chiron Real Estate is facing a deteriorating growth profile because the higher-rate environment beginning in 2022 compressed acquisition spreads, slowed external expansion, and left FFO growth negative in FY2023 and FY2024 after a +17.5% CAGR over 2017-2022. Its portfolio still sits at only ~5.1msf, 189 properties, and $1.5bn in gross assets by February 2026, while 2026 guidance was withdrawn amid a costly repositioning that adds execution risk rather than near-term earnings visibility. The stock is also exposed to concentrated tenant and geographic risk, with the top three tenants generating 19% of revenue and limited trading liquidity of $3mm-$4mm per day, leaving it vulnerable if rent growth weakens or healthcare operators face reimbursement, regulatory, or labor চাপ.